{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:05:32Z","timestamp":1790165132553,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04281-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:01Z","timestamp":1790163961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic transplantation outcomes in chronic myeloid leukemia in the era of tyrosine kinase inhibitors"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6083-5653","authenticated-orcid":false,"given":"German Jose","family":"Wernicke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia I.","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina Emilia","family":"Bendek Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Pelayes Tortosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teofilo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bentolila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Roberto","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Saslavsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marta","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Vitriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Arbelbide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel Ana","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Berro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lisa","family":"Basquiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"11","key":"4281_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2025;99(11):2191\u2013212.","journal-title":"Am J Hematol"},{"issue":"11","key":"4281_CR2","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","volume":"28","author":"JM Goldman","year":"2010","unstructured":"Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888\u201395.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4281_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"4281_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/leu.2016.246","volume":"31","author":"VS Hoffmann","year":"2017","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593\u2013601.","journal-title":"Leukemia"},{"issue":"4","key":"4281_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"7","key":"4281_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"11","key":"4281_CR7","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150\u201367.","journal-title":"Leukemia"},{"issue":"12","key":"4281_CR8","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4281_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4281_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41409-021-01472-x","volume":"57","author":"S Masouridi-Levrat","year":"2022","unstructured":"Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, et al. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2022;57(1):23\u201330.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4281_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ajh.26764","volume":"98","author":"Y Chalandon","year":"2023","unstructured":"Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, et al. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: a retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2023;98(1):112\u201321.","journal-title":"Am J Hematol"},{"issue":"6","key":"4281_CR12","doi-asserted-by":"publisher","first-page":"597.e1","DOI":"10.1016\/j.jtct.2024.03.020","volume":"30","author":"GRO Medeiros","year":"2024","unstructured":"Medeiros GRO, Funke VAM, Lima ACM, Mion ALV, Menezes I, Setubal DC, et al. The role of molecular or cytogenetic response as a favorable prognostic factor before hematopoietic stem cell transplantation for chronic myeloid leukemia. Transplant Cell Ther. 2024;30(6):597.e1-e8.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"4281_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.hemonc.2021.02.003","volume":"15","author":"F Yassine","year":"2022","unstructured":"Yassine F, Reljic T, Moustafa MA, Iqbal M, Murthy HS, Kumar A, et al. Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. Hematol Oncol Stem Cell Ther. 2022;15(1):36\u201343.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"22","key":"4281_CR14","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/cncr.30864","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123(22):4391\u2013402.","journal-title":"Cancer"},{"issue":"11","key":"4281_CR15","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/s41409-021-01410-x","volume":"56","author":"C Niederwieser","year":"2021","unstructured":"Niederwieser C, Morozova E, Zubarovskaya L, Zabelina T, Klyuchnikov E, Janson D, et al. Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML. Bone Marrow Transplant. 2021;56(11):2834\u201341.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4281_CR16","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2019.06.028","volume":"25","author":"A Radujkovic","year":"2019","unstructured":"Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transplant. 2019;25(10):2008\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4281_CR17","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","volume":"109","author":"VG Oehler","year":"2007","unstructured":"Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782\u20139.","journal-title":"Blood"},{"issue":"8","key":"4281_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/ajh.27706","volume":"100","author":"Y Okada","year":"2025","unstructured":"Okada Y, Kondo T, Miyazaki T, Shimazu Y, Minami Y, Ouchi F, et al. Optimal depth of the treatment response before allogeneic hematopoietic transplantation for chronic myeloid leukemia in chronic phase. Am J Hematol. 2025;100(8):1440\u20133.","journal-title":"Am J Hematol"},{"issue":"6","key":"4281_CR19","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/bjh.19448","volume":"204","author":"F Onida","year":"2024","unstructured":"Onida F, Gras L, Ge J, Koster L, Hamladji RM, Byrne J, et al. Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: a retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2024;204(6):2365\u201377.","journal-title":"Br J Haematol"},{"issue":"1","key":"4281_CR20","doi-asserted-by":"publisher","first-page":"93.e1","DOI":"10.1016\/j.jtct.2023.09.019","volume":"30","author":"G Ort\u00ed","year":"2024","unstructured":"Ort\u00ed G, Gras L, Koster L, Kulagin A, Byrne J, Apperley JF, et al. Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT). Transplant Cell Ther. 2024;30(1):93.e1\u201393.e12.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"4281_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/hon.3000","volume":"40","author":"Y Shimazu","year":"2022","unstructured":"Shimazu Y, Murata M, Kondo T, Minami Y, Tachibana T, Doki N, et al. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. Hematol Oncol. 2022;40(3):442\u201356.","journal-title":"Hematol Oncol"},{"issue":"3","key":"4281_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbmt.2019.10.017","volume":"26","author":"Z DeFilipp","year":"2020","unstructured":"DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2020;26(3):472\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"4281_CR23","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","volume":"9","author":"M Copland","year":"2022","unstructured":"Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial. Lancet Haematol. 2022;9(2):e121\u201332.","journal-title":"Lancet Haematol"},{"key":"4281_CR24","unstructured":"national comprehensive cancer network. Chronic myeloid leukemia, Version 2.2022. NCCN Clinical practice guidelines in oncology. Plymouth meeting, PA: National Comprehensive Cancer Network; 2021"},{"issue":"11","key":"4281_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2169\/internalmedicine.2479-23","volume":"63","author":"S Fujita","year":"2024","unstructured":"Fujita S, Kasahara H, Kato J, Koda Y, Shiroshita K, Yamaguchi K, et al. The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - a single-institution retrospective study. Intern Med. 2024;63(11):1549\u201362.","journal-title":"Intern Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04281-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:04Z","timestamp":1790163964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04281-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"alternative-id":["4281"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04281-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}